ACCESS-1 STUDY

A randomized, open-label, ravulizumab-controlled, non-inferiority study to evaluate the efficacy and safety of pozelimab and cemdisiran, an investigational combination therapy in patients with paroxysmal nocturnal hemoglobinuria who are complement inhibitor treatment-naive or have not recently received complement inhibitor therapy

Regeneron Pharmaceuticals is currently sponsoring a phase 3, randomized, open-label, active-controlled clinical research study comparing the effects of an experimental combination treatment of pozelimab and cemdisiran, versus ravulizumab treatment in adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are complement inhibitor treatment-naïve or have not received complement inhibitor therapy of eculizumab in the last 3 months or ravulizumab in the last 6 months.

The **primary objective** of this study is to evaluate the effect of 26 weeks of investigational drugs pozelimab and cemdisiran used in combination on hemolysis and red blood cell transfusions versus ravulizumab treatment in patients with active PNH.

- **Pozelimab**: An investigational human monoclonal immunoglobulin G4P (IgG4P) antibody directed against complement factor 5 (C5).
- **Cemdisiran**: An investigational synthetic siRNA targeting C5 mRNA with the goal of suppressing liver production of C5 protein.
- **Ravulizumab**: A humanized monoclonal antibody directed against C5 currently approved in some countries for the treatment of PNH.

Following a screening period, eligible patients will be randomized to receive either ravulizumab (intravenously, IV) or pozelimab and cemdisiran (subcutaneously, SC).*

siRNA=small interfering ribonucleic acid
**The first dose of pozelimab is given as an infusion.*

Please refer to the opposite side of this letter for more information on the study.

If you would like to refer a patient or request further information, please contact

Principal Investigator: _____

Phone number: _____

Affiliation: _____

By referring patients, you are neither requiring them to participate nor guaranteeing their enrollment. Patients enrolled in the study can remain in your care during their participation.

REGENERON

ACCESS-1 STUDY FACT SHEET

STUDY DESIGN

The ACCESS-1 Study is a phase 3, randomized, open-label, active-controlled clinical research study with a 26-week treatment period.

Primary objective

To evaluate the effect of 26 weeks of investigational drugs pozelimab and cemdisiran used in combination on hemolysis and red blood cell transfusions versus ravulizumab treatment in patients with active PNH who are complement inhibitor treatment-naïve or have not recently received complement inhibitor therapy.

Primary endpoints

- Percent change in LDH from baseline to week 26
- Transfusion avoidance from day 1 through week 26

STUDY PATIENT POPULATION (ABBREVIATED CRITERIA)

- Adults ≥ 18 years of age
- Confirmed diagnosis of PNH
- Active disease (≥ 1 PNH-related signs or symptoms) or history of RBC transfusion due to PNH within the last 3 months
- have not received complement inhibitor treatment of eculizumab in the last 3 months or ravulizumab in the last 6 months

DOSAGE AND ADMINISTRATION

Patients will be randomized 1:1 to the pozelimab + cemdisiran arm or the ravulizumab arm.

IV=intravenous, LDH=lactate dehydrogenase, RBC=red blood cell, SC=subcutaneous, ULN=upper limit of normal